Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

By Dr. Matthew Watson

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China.

Read the original here:
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

Related Post


categoriaGlobal News Feed commentoComments Off on Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China | dataJuly 7th, 2021

About...

This author published 3972 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research